Table 3.

Body composition and BMD before and after 5 months of gonadotropin releasing hormone agonist plus placebo (GnRH_AG+PL) or estradiol (GnRH_AG+E₂) treatment. Values are mean (SEM or 95% CI).

	GnRHAG+PL (n = 35)			GnRHAG+E2 (n = 35)
	Before	After	Within-group Change (95% CI)	Before	After	Within-group Change (95% CI)	Between-group Difference in Changea (95% CI)
Total mass (kg)	74.4 (2.7)	73.8 (2.7)	−0.6 (−1.3, 0.2)	76.6 (3.0)	76.9 (3.0)	0.3 (−0.9, 1.5)	−0.9 (−2.3, 0.5)
FFM (kg)	46.6 (1.0)	46.0 (1.0)	−0.6 (−1.0, −0.3)	48.3 (1.1)	48.7 (1.1)	0.3 (−0.2, 0.8)	−1.1 (−1.7,- 0.4)
Trunk FFM (kg)	23.3 (0.5)	23.0 (0.5)	−0.3 (−0.5, 0.0)	23.9 (0.6)	24.0 (0.5)	0.2 (−0.2, 0.5)	−0.5 (−0.9, −0.1)
Leg FFM (kg)	15.2 (0.5)	14.9 (0.4)	−0.3 (−0.5, −0.1)	16.1 (0.5)	16.2 (0.5)	0.1 (−0.1, 0.3)	−0.5 (−0.8, −0.2)
FM (kg)	27.8 (1.9)	27.8 (1.9)	0.1 (−0.6, 0.8)	28.2 (2.0)	28.2 (2.1)	0.0 (−1.0, 0.9)	0.1 (−1.1, 1.3)
Trunk FM (kg)	13.6 (1.0)	13.7 (1.1)	0.1 (−0.3, 0.5)	13.4 (1.1)	13.5 (1.1)	0.1 (−0.4, 0.7)	0.0 (−0.7, 0.6)
Leg FM (kg)	10.4 (0.7)	10.3 (0.7)	0.0 (−0.3, 0.2)	11.0 (0.8)	10.9 (0.8)	−0.1 (−0.5, 0.2)	0.1 (−0.4, 0.5)
BMD (g/cm2)
Lumbar spine	1.053 (0.018)	1.021 (0.019)	−0.032 (−0.041, −0.023)	1.083 (0.013)	1.076 (0.012)	−0.007 (−0.015, 0.001)	−0.026 (−0.038, −0.014)
Total hip	0.996 (0.020)	0.984 (0.020)	−0.012 (−0.022, −0.003)	0.984 (0.016)	0.988 (0.016)	0.003 (0.002, 0.008)	−0.015 (−0.026, −0.005)
Femoral neck	0.868 (0.018)	0.850 (0.018)	−0.018 (−0.030, −.0006)	0.871 (0.016)	0.873 (0.017)	0.002 (−0.007, 0.011)	−0.020 (−0.035, −0.005)
Trochanter	0.747 (0.018)	0.738 (0.018)	−0.009 (−0.018, −0.001)	0.738 (0.013)	0.741 (0.014)	0.003 (0.002, 0.008)	−0.013 (−0.022, −0.003)
Subtrochanter	1.176 (0.024)	1.168 (0.024)	−0.008 (−0.019, 0.002)	1.157 (0.019)	1.160 (0.019)	0.003 (−0.005, 0.011)	−0.011 (−0.024, 0.002)

^aAdjusted for baseline values; fat-free mass (FFM), fat mass (FM), bone mineral density (BMD)